Imara Revenue and Competitors

License our Company Data API

N/A

Total Funding

Estimated Revenue & Valuation

Imara's estimated annual revenue is currently $5.9M per year.(i)
Imara's estimated revenue per employee is $368,125
Imara's current valuation is $50.2M. (January 2022)

Employee Data

Imara has 16 Employees.(i)
Imara grew their employee count by 33% last year.

Imara's People

Name	Title	Email/Phone

Imara Competitors & AlternativesAdd Company

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 Ultivue	$5.2M	67	-45%	$107.3M	N/A
#2 Ohana Bioscienc...	$0.3M	2	0%	N/A	N/A
#3 Matterworks	$5.1M	33	6%	N/A	N/A
#4 Gelesis	$11.9M	77	-37%	$312.8M	N/A
#5 BOSLab	$0.9M	6	0%	N/A	N/A
#6 Akebia Therapeu...	$235M	300	-5%	$340.9M	N/A
#7 Elucidata Corpo...	$45.9M	237	-7%	$7.6M	N/A
#8 TRIANA Biomedic...	$3.9M	50	35%	N/A	N/A
#9 COTTER BROTHERS...	$5.4M	35	3%	N/A	N/A
#10 TGA BioServices	$1.6M	10	0%	N/A	N/A

Add Company

Show More Biotech Companies

What Is Imara?

Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.

keywords:N/A

N/A

Total Funding

Number of Employees

$5.9M

Revenue (est)

33%

Employee Growth %

$50.2M

Valuation

N/A

Accelerator

Imara News

2022-04-20 - Reviewing Karyopharm Therapeutics (NASDAQ:KPTI) and ...

IMARA has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio...